Oct 26, 2025
3 min read
Research shows that mRNA vaccines against Covid-19 can boost the immune system.
Researchers have found that an mRNA-based COVID-19 vaccine could potentially help patients whose tumors do not respond well to conventional immunotherapy.
The vaccine that is stored around the world during the summer during the growing season cannot help the immune system to fight acer.This is a wonderful way to read the latest news that we and our friends publish in the newspaper.
While creating MrNACINS for Brain Tumor Owners in 2016, our team, found that Mr. Pedigtric Erias, found the mrunko system to kill tumors - even if the mRNA is associated with cancer.
From this discoveryWe hypothesize that an mRNA vaccine designed to target the SARS-CoV-2 virus that causes COVID-19 would be available.It may have anti-cancer effects as well.
So we studied the clinical outcomes of more than 1,000 patients with advanced melanoma and lung cancer who received immunotherapies called immune checkpoint inhibitors.This treatment is a common approach that doctors use to train the immune system to fight cancer.It does this by blocking proteins that tumor cells make to shut down immune cells, which allows the immune system to continue to destroy the cancer.
Specifically, patients who received Pfizer or Moderna's mRNA-based COVID-19 vaccine within 100 days of starting immunotherapy were twice as likely to be alive after three years compared to those who did not receive the vaccine.Surprisingly, patients with tumors that typically do not respond well to immunotherapy saw strong benefits, with a nearly fivefold improvement in three-year overall survival.Improved survival and this association between receiving the mRNA vaccine against COVID-19 remained strong even after we controlled for factors such as disease severity and co-morbidities.
We are turning to animal models to understand the underlying mechanisms.We found that the COVID-19 mRNA vaccine acts like an alarm, triggering the immune system to recognize and kill tumor cells and overcoming the cancer's ability to shut down immune cells.When combined, vaccines and immune checkpoint inhibitors work together to unleash the power of the immune system to kill cancer cells.You can.
Why is it important?
Immunotherapy with immune checkpoint inhibitors has revolutionized cancer treatment over the past decade, creating cures for many patients previously considered incurable.However, these treatments are ineffective in patients with "cold" tumors that successfully evade immune detection.
Write down the most interesting discoveries in the world and bring them to your box.
Our research shows that the MrN vaccine can offer those who need to change the process from "cold" to "hot".If it does well in our upcoming clinical trials, we hope that the cheap, free products can be extended to millions of patients who would not benefit from this treatment.
This is subject to further investigation
Unlike infectious disease vaccines, which are used to prevent infection, therapeutic cancer vaccines are used to help train cancer patients' immune systems to better fight tumors.
We and many others are currently working hard to create personalized MRNA vaccines for cancer patients.This involves taking a small sample of a patient's tumor and using a learning algorithm technique to predict which proteins in the tumor would be the best targets for a vaccine.However, this method is expensive and difficult to carry out.
In contrast, covid-19 mRNA vaccines do not need to be customized, are widely available worldwide at little or no cost, and can be administered at any time during a patient's treatment.Our findings that covid-19 mRNA vaccines have significant antitumor effects give us hope to extend the anticancer benefits of mRNA vaccines to everyone.
To achieve this goal, we are preparing to test this treatment strategy in patients with a national clinical trial in colon cancer.Individuals who have acquired co-immunoprecipitation are excluded from receiving the co-19 vaccine or receive no treatment.
This study will tell us whether COVID-19 mRNA vaccines should be included as part of standard care for patients with immune checkpoint inhibitors.Ultimately, we hope that this approach will help many immunotherapy patients, and especially those who currently lack effective treatment options.
This research is an example of how tools born of a global pandemic can provide new weapons against cancer and rapidly extend the benefits of existing treatments to millions of patients.We hope that by utilizing known vaccines in new ways, we can extend the life-saving benefits of immunotherapy to previously underserved cancer patients.
This edited article is republished from The Conversation under a Creative Commons license.Read the original article.
Adam Grrippin completed his medical and doctoral training at the University of Florida, where he developed an mRNA-nanoparticle platform that is currently in first-in-human clinical trials for the treatment of brain tumors.He has published several peer-reviewed papers, including Nano ACs and Nanoletters.Grippin's research achievements have been recognized with several awards and fellowships, including the Ruth L. Kirschstein national research service and induction into the University of Florida Hall of Fame.His research interests are in the development and translation of novel agents for Immunotherapy.
You must verify your public screen name before commenting
Please sign in and come back, you will be prompted to enter your display name.
